| Field | Row 1 |
|---|---|
| adsh | 0001628280-25-022401 |
| cik | 1665988 |
| name | BIOVENTUS INC. |
| sic | 3841 |
| countryba | US |
| stprba | NC |
| cityba | DURHAM |
| zipba | 27703 |
| bas1 | 4721 EMPEROR BOULEVARD, SUITE 100 |
| bas2 | |
| baph | (919) 474-6700 |
| countryma | US |
| stprma | NC |
| cityma | DURHAM |
| zipma | 27703 |
| mas1 | 4721 EMPEROR BOULEVARD, SUITE 100 |
| mas2 | |
| countryinc | US |
| stprinc | DE |
| ein | 810980861 |
| former | |
| changed | |
| afs | 2-ACC |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250506 |
| accepted | 2025-05-06 07:39:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | bvs-20250329_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0001628280-25-022401 | 20250331 | Accounts Payable Current | 19197000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Accounts Receivable Net Current | 118082000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | 295000.0000 | USD | 1 | us-gaap/2024 | Business Acquisition= Bioness Inc; | ||
| 0001628280-25-022401 | 20241231 | Business Combination Contingent Consideration Liability Current | 19573000.0000 | USD | 0 | us-gaap/2024 | Business Acquisition= Bioness Inc; Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001628280-25-022401 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 41582000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 22802000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20210228 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class B; | ||
| 0001628280-25-022401 | 20241231 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class B; | ||
| 0001628280-25-022401 | 20250331 | Common Stock Shares Outstanding | 66231388.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class A; Equity Components= Common Stock; | ||
| 0001628280-25-022401 | 20250331 | Deferred Income Taxes And Tax Credits | 43000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Depreciation Depletion And Amortization | 11865000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Material Reconciling Items; | ||
| 0001628280-25-022401 | 20240331 | Earnings Per Share Basic | -0.0700 | USD | 1 | us-gaap/2024 | Restatement= Scenario Previously Reported; | ||
| 0001628280-25-022401 | 20250331 | Earnings Per Share Diluted | -0.0400 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Increase Decrease In Other Operating Capital Net | -780000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Intangible Assets Net Excluding Goodwill | 395731000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Liabilities | 542352000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Long Term Debt Current | 27339000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Net Cash Provided By Used In Investing Activities | -1000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240930 | Net Income Loss | -341000.0000 | USD | 1 | us-gaap/2024 | Restatement= Restatement Adjustment; | ||
| 0001628280-25-022401 | 20250331 | Net Income Loss Attributable To Noncontrolling Interest | -685000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Operating Income Loss | 4928000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | 633000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Payments To Acquire Property Plant And Equipment | 826000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Preferred Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 27012000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Repayments Of Long Term Lines Of Credit | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Retained Earnings Accumulated Deficit | -357661000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 15176000.0000 | USD | 1 | us-gaap/2024 | Business Segments= International Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-022401 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 6052000.0000 | USD | 1 | us-gaap/2024 | Geographical= Non Us; Product Or Service= Pain Treatments; | ||
| 0001628280-25-022401 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 25304000.0000 | USD | 1 | us-gaap/2024 | Geographical= U S; Product Or Service= Restorative Therapies; | ||
| 0001628280-25-022401 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 2734000.0000 | USD | 1 | us-gaap/2024 | Geographical= Non Us; Product Or Service= Restorative Therapies; | ||
| 0001628280-25-022401 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 4390000.0000 | USD | 1 | us-gaap/2024 | Geographical= Non Us; Product Or Service= Surgical Solutions; | ||
| 0001628280-25-022401 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 110520000.0000 | USD | 1 | us-gaap/2024 | Geographical= U S; | ||
| 0001628280-25-022401 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 325000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Aoci Including Portion Attributable To Noncontrolling Interest; | ||
| 0001628280-25-022401 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 185479000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Stock Issued During Period Value New Issues | 1000.0000 | USD | 1 | us-gaap/2024 | Class Of Stock= Common Class A; Equity Components= Common Stock; | ||
| 0001628280-25-022401 | 20240331 | Stock Issued During Period Value New Issues | 289000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-022401 | 20250331 | Stock Issued During Period Value New Issues | 150000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Weighted Average Number Of Shares Outstanding Basic | 63380187.0000 | shares | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Weighted Average Number Of Shares Outstanding Basic | 66008683.0000 | shares | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Accrued Liabilities Current | 135879000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 2990000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 2435000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-022401 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 393000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001628280-25-022401 | 20250331 | Assets Current | 249367000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Capital Expenditures Incurred But Not Yet Paid | 140000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -11791000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0001628280-25-022401 | 20210228 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class A; | ||
| 0001628280-25-022401 | 20241231 | Common Stock Shares Issued | 15786737.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class B; | ||
| 0001628280-25-022401 | 20231231 | Common Stock Shares Outstanding | 63267436.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class A; Equity Components= Common Stock; | ||
| 0001628280-25-022401 | 20240331 | Common Stock Shares Outstanding | 63672170.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class A; Equity Components= Common Stock; | ||
| 0001628280-25-022401 | 20241231 | Common Stock Shares Outstanding | 65758341.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class A; | ||
| 0001628280-25-022401 | 20241231 | Common Stock Value | 66000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class A; | ||
| 0001628280-25-022401 | 20241231 | Deferred Income Tax Assets Net | 4745000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Depreciation And Amortization | 1755000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Depreciation Depletion And Amortization | 11785000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Gain Loss On Sale Of Business | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Goodwill | 7462000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -5474000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -3417000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Income Tax Expense Benefit | -95000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Increase Decrease In Other Operating Capital Net | 1397000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Liabilities | 505935000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Net Income Loss | -2637000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Noncontrolling Interest Increase Decrease From Business Combination | -319000.0000 | USD | 1 | 0001628280-25-022401 | Equity Components= Noncontrolling Interest; | ||
| 0001628280-25-022401 | 20240331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | -585000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Other Liabilities Current | 4359000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Other Operating Activities Cash Flow Statement | 581000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Proceeds From Issuance Of Common Stock | 150000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Proceeds From Long Term Lines Of Credit | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Profit Loss | -2637000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001628280-25-022401 | 20250331 | Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 25722000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 114281000.0000 | USD | 1 | us-gaap/2024 | Business Segments= U S Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-022401 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 5170000.0000 | USD | 1 | us-gaap/2024 | Geographical= Non Us; Product Or Service= Restorative Therapies; | ||
| 0001628280-25-022401 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 50637000.0000 | USD | 1 | us-gaap/2024 | Geographical= U S; Product Or Service= Pain Treatments; | ||
| 0001628280-25-022401 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 16000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class B; Equity Components= Common Stock; | ||
| 0001628280-25-022401 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 16000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class B; Equity Components= Common Stock; | ||
| 0001628280-25-022401 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 497297000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-022401 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 66000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class A; Equity Components= Common Stock; | ||
| 0001628280-25-022401 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 16000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class B; Equity Components= Common Stock; | ||
| 0001628280-25-022401 | 20250331 | Weighted Average Number Of Diluted Shares Outstanding | 66008683.0000 | shares | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0001628280-25-022401 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class A; | ||
| 0001628280-25-022401 | 20241231 | Common Stock Shares Issued | 65758341.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class A; | ||
| 0001628280-25-022401 | 20231231 | Common Stock Shares Outstanding | 15786737.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class B; Equity Components= Common Stock; | ||
| 0001628280-25-022401 | 20241231 | Common Stock Shares Outstanding | 65758341.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class A; Equity Components= Common Stock; | ||
| 0001628280-25-022401 | 20250331 | Common Stock Shares Outstanding | 15786737.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class B; Equity Components= Common Stock; | ||
| 0001628280-25-022401 | 20240331 | Cost Of Goods And Services Sold | 41077000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Depreciation And Amortization | 1593000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Depreciation Depletion And Amortization | 11865000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Earnings Per Share Diluted | -0.0800 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -399000.0000 | USD | 1 | us-gaap/2024 | Restatement= Restatement Adjustment; | ||
| 0001628280-25-022401 | 20241231 | Intangible Assets Net Excluding Goodwill | 404729000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Interest Income Expense Nonoperating Net | -7509000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Inventory Net | 94045000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Net Cash Provided By Used In Financing Activities | -4242000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Net Cash Provided By Used In Investing Activities | -826000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Net Cash Provided By Used In Operating Activities | -6005000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Noncontrolling Interest Increase Decrease From Business Combination | 0.0000 | USD | 1 | 0001628280-25-022401 | |||
| 0001628280-25-022401 | 20250228 | Payment For Contingent Consideration Liability Financing Activities | 9000000.0000 | USD | 0 | us-gaap/2024 | Business Acquisition= Bioness Inc; Contingent Consideration By Type= Earn Out Payments For Maintaining Centers For Medicare Medicaid; | ||
| 0001628280-25-022401 | 20250331 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Proceeds From Payments For Other Financing Activities | -203000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Profit Loss | -5982000.0000 | USD | 1 | us-gaap/2024 | Restatement= Scenario Previously Reported; | ||
| 0001628280-25-022401 | 20240331 | Provision For Doubtful Accounts | -976000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Research And Development Expense | 30000.0000 | USD | 1 | us-gaap/2024 | Restatement= Restatement Adjustment; | ||
| 0001628280-25-022401 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 38340000.0000 | USD | 1 | us-gaap/2024 | Geographical= U S; Product Or Service= Surgical Solutions; | ||
| 0001628280-25-022401 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 13356000.0000 | USD | 1 | us-gaap/2024 | Business Segments= International Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-022401 | 20240331 | Selling General And Administrative Expense | 78406000.0000 | USD | 1 | us-gaap/2024 | Restatement= Scenario Previously Reported; | ||
| 0001628280-25-022401 | 20250331 | Selling General And Administrative Expense | 73502000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Share Based Compensation | 2414000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 494254000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-022401 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 37664000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001628280-25-022401 | 20240331 | Stock Issued During Period Value New Issues | 290000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Accrued Liabilities Current | 103283000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Additional Paid In Capital | 508092000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 2021000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-022401 | 20241231 | Business Combination Contingent Consideration Liability Current | 19573000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Business Combination Contingent Consideration Liability Current | 10573000.0000 | USD | 0 | us-gaap/2024 | Business Acquisition= Bioness Inc; Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001628280-25-022401 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -18780000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Accounts Payable Current | 23690000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | 0.0000 | USD | 1 | us-gaap/2024 | Business Acquisition= Bioness Inc; | ||
| 0001628280-25-022401 | 20210228 | Common Stock Shares Authorized | 50000000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class B; | ||
| 0001628280-25-022401 | 20241231 | Common Stock Shares Authorized | 50000000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class B; | ||
| 0001628280-25-022401 | 20241231 | Common Stock Value | 16000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class B; | ||
| 0001628280-25-022401 | 20240331 | Comprehensive Income Loss Attributable To Noncontrolling Interest Continuing Operations | 79000.0000 | USD | 1 | 0001628280-25-022401 | Restatement= Restatement Adjustment; | ||
| 0001628280-25-022401 | 20240331 | Comprehensive Income Loss Attributable To Noncontrolling Interest Continuing Operations | 1528000.0000 | USD | 1 | 0001628280-25-022401 | Restatement= Scenario Previously Reported; | ||
| 0001628280-25-022401 | 20250331 | Comprehensive Income Loss Attributable To Noncontrolling Interest Continuing Operations | 563000.0000 | USD | 1 | 0001628280-25-022401 | |||
| 0001628280-25-022401 | 20240331 | Comprehensive Income Net Of Tax | -320000.0000 | USD | 1 | us-gaap/2024 | Restatement= Restatement Adjustment; | ||
| 0001628280-25-022401 | 20250331 | Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | -2689000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Cost Of Goods And Services Sold Depreciation And Amortization | 10025000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Gross Profit | 83056000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Income Tax Expense Benefit | 907000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Increase Decrease In Accounts Payable And Accrued Liabilities | -7332000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Increase Decrease In Accounts Receivable | -9004000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Inventory Net | 92475000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Long Term Debt Noncurrent | 308593000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Net Cash Provided By Used In Financing Activities | 947000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240630 | Net Income Loss | -1690000.0000 | USD | 1 | us-gaap/2024 | Restatement= Restatement Adjustment; | ||
| 0001628280-25-022401 | 20240331 | Net Income Loss Attributable To Noncontrolling Interest | -1491000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Net Income Loss Attributable To Noncontrolling Interest | -79000.0000 | USD | 1 | us-gaap/2024 | Restatement= Restatement Adjustment; | ||
| 0001628280-25-022401 | 20240331 | Noncontrolling Interest Increase Decrease From Business Combination | 319000.0000 | USD | 1 | 0001628280-25-022401 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-022401 | 20240331 | Nonoperating Income Expense | -10402000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Other Nonoperating Income Expense | -777000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Payment For Contingent Consideration Liability Financing Activities | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Preferred Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Profit Loss | -399000.0000 | USD | 1 | us-gaap/2024 | Restatement= Restatement Adjustment; | ||
| 0001628280-25-022401 | 20240331 | Research And Development Expense | 2627000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Research And Development Expense | 2597000.0000 | USD | 1 | us-gaap/2024 | Restatement= Scenario Previously Reported; | ||
| 0001628280-25-022401 | 20241231 | Retained Earnings Accumulated Deficit | -355078000.0000 | USD | 0 | us-gaap/2024 | Restatement= Scenario Previously Reported; | ||
| 0001628280-25-022401 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 110520000.0000 | USD | 1 | us-gaap/2024 | Business Segments= U S Segment; Consolidation Items= Operating Segments; | ||
| 0001628280-25-022401 | 20240331 | Selling General And Administrative Expense | 369000.0000 | USD | 1 | us-gaap/2024 | Restatement= Restatement Adjustment; | ||
| 0001628280-25-022401 | 20240331 | Share Based Compensation | 2990000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Stockholders Equity | 147940000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 63000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class A; Equity Components= Common Stock; | ||
| 0001628280-25-022401 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 794000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Aoci Including Portion Attributable To Noncontrolling Interest; | ||
| 0001628280-25-022401 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 46156000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001628280-25-022401 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -326426000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001628280-25-022401 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -357661000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001628280-25-022401 | 20240331 | Stock Issued During Period Shares New Issues | 404734.0000 | shares | 1 | us-gaap/2024 | Class Of Stock= Common Class A; Equity Components= Common Stock; | ||
| 0001628280-25-022401 | 20240331 | Weighted Average Number Of Diluted Shares Outstanding | 63380187.0000 | shares | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Additional Paid In Capital | 510422000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | 295000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Accumulated Other Comprehensive Income Loss Net Of Tax | -2573000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Business Combination Contingent Consideration Liability Current | 10573000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Business Combination Contingent Consideration Liability Current | 10573000.0000 | USD | 0 | us-gaap/2024 | Business Acquisition= Bioness Inc; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001628280-25-022401 | 20241231 | Common Stock Shares Outstanding | 15786737.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class B; Equity Components= Common Stock; | ||
| 0001628280-25-022401 | 20250331 | Common Stock Shares Outstanding | 66231388.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class A; | ||
| 0001628280-25-022401 | 20240331 | Comprehensive Income Net Of Tax | -5039000.0000 | USD | 1 | us-gaap/2024 | Restatement= Scenario Previously Reported; | ||
| 0001628280-25-022401 | 20240331 | Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | -6966000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Earnings Per Share Basic | -0.0100 | USD | 1 | us-gaap/2024 | Restatement= Restatement Adjustment; | ||
| 0001628280-25-022401 | 20240331 | Earnings Per Share Diluted | -0.0700 | USD | 1 | us-gaap/2024 | Restatement= Scenario Previously Reported; | ||
| 0001628280-25-022401 | 20250331 | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 430000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Foreign Currency Transaction Gain Loss Unrealized | 242000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -5075000.0000 | USD | 1 | us-gaap/2024 | Restatement= Scenario Previously Reported; | ||
| 0001628280-25-022401 | 20250331 | Increase Decrease In Accounts Payable And Accrued Liabilities | -39104000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Increase Decrease In Accounts Receivable | 1958000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Increase Decrease In Inventories | 4070000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Liabilities And Stockholders Equity | 727956000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Liabilities Current | 210398000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Net Cash Provided By Used In Operating Activities | -19331000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Net Income Loss | -4890000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Net Income Loss | -4570000.0000 | USD | 1 | us-gaap/2024 | Restatement= Scenario Previously Reported; | ||
| 0001628280-25-022401 | 20241231 | Net Income Loss | -2583000.0000 | USD | 4 | us-gaap/2024 | Restatement= Restatement Adjustment; | ||
| 0001628280-25-022401 | 20240331 | Operating Income Loss | 5327000.0000 | USD | 1 | us-gaap/2024 | Restatement= Scenario Previously Reported; | ||
| 0001628280-25-022401 | 20250331 | Operating Income Loss | 4869000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Other Nonoperating Income Expense | -63000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Other Operating Activities Cash Flow Statement | 381000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Payment For Contingent Consideration Liability Financing Activities | 9000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Prepaid Expense And Other Assets Current | 14438000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Proceeds From Long Term Lines Of Credit | 15000000.0000 | USD | 1 | us-gaap/2024 | Credit Facility= Line Of Credit; Longterm Debt Type= Revolving Credit Facility; | ||
| 0001628280-25-022401 | 20240331 | Proceeds From Payments For Acquisition Of Intangible Assets And Investments | -709000.0000 | USD | 1 | 0001628280-25-022401 | |||
| 0001628280-25-022401 | 20240331 | Profit Loss | -4890000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001628280-25-022401 | 20240331 | Repayments Of Other Long Term Debt | 3056000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 3954000.0000 | USD | 1 | us-gaap/2024 | Geographical= Non Us; Product Or Service= Surgical Solutions; | ||
| 0001628280-25-022401 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 114281000.0000 | USD | 1 | us-gaap/2024 | Geographical= U S; | ||
| 0001628280-25-022401 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 6232000.0000 | USD | 1 | us-gaap/2024 | Geographical= Non Us; Product Or Service= Pain Treatments; | ||
| 0001628280-25-022401 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 40844000.0000 | USD | 1 | us-gaap/2024 | Geographical= U S; Product Or Service= Surgical Solutions; | ||
| 0001628280-25-022401 | 20240331 | Selling General And Administrative Expense | 78775000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 64000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class A; Equity Components= Common Stock; | ||
| 0001628280-25-022401 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 510422000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-022401 | 20250331 | Stock Issued During Period Value New Issues | 150000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-022401 | 20250331 | Accumulated Other Comprehensive Income Loss Net Of Tax | -2062000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Assets | 727956000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Assets Current | 275610000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Business Combination Contingent Consideration Liability Current | 19573000.0000 | USD | 0 | us-gaap/2024 | Business Acquisition= Bioness Inc; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001628280-25-022401 | 20250331 | Cash And Cash Equivalents At Carrying Value | 22802000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 36964000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 25173000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class B; | ||
| 0001628280-25-022401 | 20250331 | Common Stock Shares Issued | 66231388.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class A; | ||
| 0001628280-25-022401 | 20240331 | Common Stock Shares Outstanding | 15786737.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class B; Equity Components= Common Stock; | ||
| 0001628280-25-022401 | 20250331 | Common Stock Value | 66000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class A; | ||
| 0001628280-25-022401 | 20240331 | Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | -399000.0000 | USD | 1 | us-gaap/2024 | Restatement= Restatement Adjustment; | ||
| 0001628280-25-022401 | 20250331 | Deferred Income Tax Assets Net | 4745000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Deferred Income Tax Liabilities Net | 564000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Deferred Income Tax Liabilities Net | 607000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Earnings Per Share Basic | -0.0400 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -544000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Gain Loss On Sale Of Business | -81000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Material Reconciling Items; | ||
| 0001628280-25-022401 | 20240331 | Interest Income Expense Nonoperating Net | -10339000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Interest Income Expense Nonoperating Net | -10339000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Material Reconciling Items; | ||
| 0001628280-25-022401 | 20250331 | Interest Income Expense Nonoperating Net | -7509000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Material Reconciling Items; | ||
| 0001628280-25-022401 | 20250331 | Long Term Debt Current | 37339000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Long Term Debt Current | 27339000.0000 | USD | 0 | us-gaap/2024 | Longterm Debt Type= Term Loan; | ||
| 0001628280-25-022401 | 20250331 | Long Term Investments | 1756000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Noncontrolling Interest Increase Decrease From Business Combination | 0.0000 | USD | 1 | 0001628280-25-022401 | |||
| 0001628280-25-022401 | 20250331 | Noncontrolling Interest Increase Decrease From Business Combination | 159000.0000 | USD | 1 | 0001628280-25-022401 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-022401 | 20240331 | Operating Income Loss | -399000.0000 | USD | 1 | us-gaap/2024 | Restatement= Restatement Adjustment; | ||
| 0001628280-25-022401 | 20250331 | Operating Lease Right Of Use Asset | 6631000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | -469000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Aoci Including Portion Attributable To Noncontrolling Interest; | ||
| 0001628280-25-022401 | 20250331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | 511000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Aoci Including Portion Attributable To Noncontrolling Interest; | ||
| 0001628280-25-022401 | 20241231 | Other Liabilities Noncurrent | 23102000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Other Liabilities Noncurrent | 21984000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Payment Of Debt Refinancing Costs | 0.0000 | USD | 1 | 0001628280-25-022401 | |||
| 0001628280-25-022401 | 20240331 | Payments To Acquire Property Plant And Equipment | 291000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Prepaid Expense And Other Assets Current | 14160000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Proceeds From Issuance Of Common Stock | 177000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20220630 | Proceeds From Long Term Lines Of Credit | 80000000.0000 | USD | 0 | us-gaap/2024 | Credit Facility= Line Of Credit; Debt Instrument= Term Loan Facility July2022; Longterm Debt Type= Secured Debt; | ||
| 0001628280-25-022401 | 20250331 | Proceeds From Long Term Lines Of Credit | 15000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Proceeds From Payments For Acquisition Of Intangible Assets And Investments | 0.0000 | USD | 1 | 0001628280-25-022401 | |||
| 0001628280-25-022401 | 20240331 | Proceeds From Payments For Other Financing Activities | -183000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Provision For Doubtful Accounts | 650000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Retained Earnings Accumulated Deficit | -2583000.0000 | USD | 0 | us-gaap/2024 | Restatement= Restatement Adjustment; | ||
| 0001628280-25-022401 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 13143000.0000 | USD | 1 | us-gaap/2024 | Concentration Risk By Benchmark= Sales Revenue Net; Concentration Risk By Type= Customer Concentration Risk; Major Customers= Customer One; | ||
| 0001628280-25-022401 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 15176000.0000 | USD | 1 | us-gaap/2024 | Geographical= Non Us; | ||
| 0001628280-25-022401 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 123876000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 13356000.0000 | USD | 1 | us-gaap/2024 | Geographical= Non Us; | ||
| 0001628280-25-022401 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 16990000.0000 | USD | 1 | us-gaap/2024 | Geographical= U S; Product Or Service= Restorative Therapies; | ||
| 0001628280-25-022401 | 20250331 | Stockholders Equity | 148144000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 16000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class B; Equity Components= Common Stock; | ||
| 0001628280-25-022401 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -2062000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Aoci Including Portion Attributable To Noncontrolling Interest; | ||
| 0001628280-25-022401 | 20250331 | Stock Issued During Period Shares New Issues | 473047.0000 | shares | 1 | us-gaap/2024 | Class Of Stock= Common Class A; Equity Components= Common Stock; | ||
| 0001628280-25-022401 | 20241231 | Accounts Receivable Net Current | 127393000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 555000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001628280-25-022401 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 2414000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Capital Expenditures Incurred But Not Yet Paid | 218000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class A; | ||
| 0001628280-25-022401 | 20210228 | Common Stock Shares Authorized | 250000000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class A; | ||
| 0001628280-25-022401 | 20241231 | Common Stock Shares Authorized | 250000000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class A; | ||
| 0001628280-25-022401 | 20250331 | Common Stock Shares Issued | 15786737.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class B; | ||
| 0001628280-25-022401 | 20250331 | Common Stock Shares Outstanding | 15786737.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class B; | ||
| 0001628280-25-022401 | 20250331 | Common Stock Value | 16000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class B; | ||
| 0001628280-25-022401 | 20240331 | Comprehensive Income Net Of Tax | -5359000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | -6567000.0000 | USD | 1 | us-gaap/2024 | Restatement= Scenario Previously Reported; | ||
| 0001628280-25-022401 | 20250331 | Cost Of Goods And Services Sold | 40820000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Deferred Income Taxes And Tax Credits | 81000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Depreciation Depletion And Amortization | 11785000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Material Reconciling Items; | ||
| 0001628280-25-022401 | 20240331 | Earnings Per Share Basic | -0.0800 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Gain Loss On Sale Of Business | -81000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Goodwill | 7462000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Gross Profit | 88380000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Increase Decrease In Inventories | 1881000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Liabilities And Stockholders Equity | 691414000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Liabilities Current | 174751000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Long Term Debt Current | 10000000.0000 | USD | 0 | us-gaap/2024 | Credit Facility= Revolving Credit Facility; | ||
| 0001628280-25-022401 | 20241231 | Long Term Investments | 1892000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Minority Interest | 37664000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Minority Interest | 37335000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Noncontrolling Interest Increase Decrease From Business Combination | -159000.0000 | USD | 1 | 0001628280-25-022401 | Equity Components= Noncontrolling Interest; | ||
| 0001628280-25-022401 | 20241231 | Operating Lease Right Of Use Asset | 6506000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20210228 | Preferred Stock Shares Authorized | 10000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Preferred Stock Shares Authorized | 10000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Profit Loss | -1491000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001628280-25-022401 | 20250331 | Profit Loss | -3322000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Repayments Of Long Term Lines Of Credit | 5000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Research And Development Expense | 3011000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 52686000.0000 | USD | 1 | us-gaap/2024 | Geographical= U S; Product Or Service= Pain Treatments; | ||
| 0001628280-25-022401 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 508092000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-022401 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -360298000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001628280-25-022401 | 20241231 | Additional Paid In Capital | 2583000.0000 | USD | 0 | us-gaap/2024 | Restatement= Restatement Adjustment; | ||
| 0001628280-25-022401 | 20241231 | Additional Paid In Capital | 505509000.0000 | USD | 0 | us-gaap/2024 | Restatement= Scenario Previously Reported; | ||
| 0001628280-25-022401 | 20250331 | Assets | 691414000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Cash And Cash Equivalents At Carrying Value | 41582000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Common Stock Shares Authorized | 250000000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class A; | ||
| 0001628280-25-022401 | 20250331 | Common Stock Shares Authorized | 50000000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class B; | ||
| 0001628280-25-022401 | 20241231 | Common Stock Shares Outstanding | 15786737.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class B; | ||
| 0001628280-25-022401 | 20240331 | Comprehensive Income Loss Attributable To Noncontrolling Interest Continuing Operations | 1607000.0000 | USD | 1 | 0001628280-25-022401 | |||
| 0001628280-25-022401 | 20250331 | Comprehensive Income Net Of Tax | -2126000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Cost Of Goods And Services Sold Depreciation And Amortization | 10265000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Foreign Currency Transaction Gain Loss Unrealized | -377000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Long Term Debt Noncurrent | 308288000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Net Income Loss | -320000.0000 | USD | 1 | us-gaap/2024 | Restatement= Restatement Adjustment; | ||
| 0001628280-25-022401 | 20240331 | Net Income Loss Attributable To Noncontrolling Interest | -1412000.0000 | USD | 1 | us-gaap/2024 | Restatement= Scenario Previously Reported; | ||
| 0001628280-25-022401 | 20250331 | Nonoperating Income Expense | -8286000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | -116000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001628280-25-022401 | 20250331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | 122000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001628280-25-022401 | 20241231 | Other Liabilities Current | 3917000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Payment Of Debt Refinancing Costs | 1180000.0000 | USD | 1 | 0001628280-25-022401 | |||
| 0001628280-25-022401 | 20250331 | Preferred Stock Shares Authorized | 10000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Profit Loss | -6381000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Profit Loss | -685000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001628280-25-022401 | 20250331 | Repayments Of Other Long Term Debt | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Retained Earnings Accumulated Deficit | -360298000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 129457000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 13594000.0000 | USD | 1 | us-gaap/2024 | Concentration Risk By Benchmark= Sales Revenue Net; Concentration Risk By Type= Customer Concentration Risk; Major Customers= Customer One; | ||
| 0001628280-25-022401 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 221118000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 47527000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001628280-25-022401 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -321536000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001628280-25-022401 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 217432000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 185604000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022401 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -2573000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Aoci Including Portion Attributable To Noncontrolling Interest; | ||
| 0001628280-25-022401 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 66000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class A; Equity Components= Common Stock; | ||
| 0001628280-25-022401 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 37335000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Noncontrolling Interest; |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Increase Decrease In Accounts Receivable | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Accounts Receivable | The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. |
| Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | D | C | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Revenue from Contract with Customer, Excluding Assessed Tax | Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. |
| Gain Loss On Sale Of Business | us-gaap/2024 | 0 | 0 | monetary | D | C | Gain (Loss) on Disposition of Business | Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant. |
| Depreciation And Amortization | us-gaap/2024 | 0 | 0 | monetary | D | D | Depreciation, Depletion and Amortization, Nonproduction | The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. |
| Payments To Acquire Property Plant And Equipment | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Property, Plant, and Equipment | The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Including Portion Attributable to Noncontrolling Interest | Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. |
| Accounts Receivable Net Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Accounts Receivable, after Allowance for Credit Loss, Current | Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. |
| Comprehensive Income Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Deferred Income Tax Assets Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Deferred Income Tax Assets, Net | Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting. |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | D | C | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. |
| Interest Income Expense Nonoperating Net | us-gaap/2024 | 0 | 0 | monetary | D | C | Interest Income (Expense), Nonoperating | Amount of interest income (expense) classified as nonoperating. |
| Liabilities | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities | Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. |
| Liabilities And Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Net Income Loss Attributable To Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Income (Loss) Attributable to Noncontrolling Interest | Amount of Net Income (Loss) attributable to noncontrolling interest. |
| Retained Earnings Accumulated Deficit | us-gaap/2024 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Proceeds From Payments For Acquisition Of Intangible Assets And Investments | 0001628280-25-022401 | 1 | 0 | monetary | D | D | Proceeds From (Payments For) Acquisition Of Intangible Assets And Investments | Proceeds From (Payments For) Acquisition Of Intangible Assets And Investments |
| Additional Paid In Capital | us-gaap/2024 | 0 | 0 | monetary | I | C | Additional Paid in Capital | Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. |
| Common Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Common Stock, Par or Stated Value Per Share | Face amount or stated value per share of common stock. | |
| Common Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Income Tax Expense Benefit | us-gaap/2024 | 0 | 0 | monetary | D | D | Income Tax Expense (Benefit) | Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. |
| Net Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
| Other Operating Activities Cash Flow Statement | us-gaap/2024 | 0 | 0 | monetary | D | D | Other Operating Activities, Cash Flow Statement | Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities). |
| Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Attributable to Parent | Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. |
| Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Diluted | The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | I | C | Accumulated Other Comprehensive Income (Loss), Net of Tax | Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. |
| Noncontrolling Interest Increase Decrease From Business Combination | 0001628280-25-022401 | 1 | 0 | monetary | D | C | Noncontrolling? Interest ?Increase? (Decrease) From ?Business? Combination | Noncontrolling? Interest ?Increase? (Decrease) From ?Business? Combination |
| Assets | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Business Combination Contingent Consideration Liability Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Business Combination, Contingent Consideration, Liability, Current | Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer. |
| Common Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | |
| Cost Of Goods And Services Sold | us-gaap/2024 | 0 | 0 | monetary | D | D | Cost of Goods and Services Sold | The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. |
| Earnings Per Share Diluted | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | 0 | 0 | monetary | D | D | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations | Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Foreign Currency Transaction Gain Loss Unrealized | us-gaap/2024 | 0 | 0 | monetary | D | C | Unrealized Gain (Loss), Foreign Currency Transaction, before Tax | Amount, before tax, of unrealized gain (loss) from foreign currency transaction. |
| Gross Profit | us-gaap/2024 | 0 | 0 | monetary | D | C | Gross Profit | Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. |
| Increase Decrease In Inventories | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Inventories | The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. |
| Operating Lease Right Of Use Asset | us-gaap/2024 | 0 | 0 | monetary | I | D | Operating Lease, Right-of-Use Asset | Amount of lessee's right to use underlying asset under operating lease. |
| Repayments Of Other Long Term Debt | us-gaap/2024 | 0 | 0 | monetary | D | C | Repayments of Other Long-Term Debt | Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer. |
| Accrued Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accrued Liabilities, Current | Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Depreciation Depletion And Amortization | us-gaap/2024 | 0 | 0 | monetary | D | D | Depreciation, Depletion and Amortization | The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. |
| Increase Decrease In Other Operating Capital Net | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Other Operating Assets and Liabilities, Net | Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other. |
| Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax | Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. |
| Preferred Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Issued | Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. | |
| Selling General And Administrative Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Selling, General and Administrative Expense | The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. |
| Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Noncash Expense | Amount of noncash expense for share-based payment arrangement. |
| Nonoperating Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Nonoperating Income (Expense) | The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). |
| Other Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Other Liabilities, Current | Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer. |
| Payment Of Debt Refinancing Costs | 0001628280-25-022401 | 1 | 0 | monetary | D | C | Payment Of Debt Refinancing Costs | Payment Of Debt Refinancing Costs |
| Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash and Cash Equivalents, at Carrying Value | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. |
| Profit Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | us-gaap/2024 | 0 | 0 | monetary | D | D | Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability | Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. |
| Goodwill | us-gaap/2024 | 0 | 0 | monetary | I | D | Goodwill | Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. |
| Intangible Assets Net Excluding Goodwill | us-gaap/2024 | 0 | 0 | monetary | I | D | Intangible Assets, Net (Excluding Goodwill) | Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. |
| Long Term Investments | us-gaap/2024 | 0 | 0 | monetary | I | D | Long-Term Investments | The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle). |
| Net Cash Provided By Used In Operating Activities | us-gaap/2024 | 0 | 0 | monetary | D | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | |
| Operating Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Other Liabilities Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Other Liabilities, Noncurrent | Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. |
| Prepaid Expense And Other Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Prepaid Expense and Other Assets, Current | Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. |
| Proceeds From Long Term Lines Of Credit | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Long-Term Lines of Credit | The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer. |
| Proceeds From Payments For Other Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from (Payments for) Other Financing Activities | Amount of cash inflow (outflow) from financing activities classified as other. |
| Capital Expenditures Incurred But Not Yet Paid | us-gaap/2024 | 0 | 0 | monetary | D | C | Capital Expenditures Incurred but Not yet Paid | Future cash outflow to pay for purchases of fixed assets that have occurred. |
| Research And Development Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Research and Development Expense | Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. |
| Common Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Inventory Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Inventory, Net | Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. |
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | us-gaap/2024 | 0 | 0 | monetary | I | D | Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization | Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset. |
| Accounts Payable Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accounts Payable, Current | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Stock Issued During Period Shares New Issues | us-gaap/2024 | 0 | 0 | shares | D | Stock Issued During Period, Shares, New Issues | Number of new stock issued during the period. | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | 0 | 0 | monetary | D | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Commitments And Contingencies | us-gaap/2024 | 0 | 0 | monetary | I | C | Commitments and Contingencies | Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. |
| Common Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares Authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | |
| Cost Of Goods And Services Sold Depreciation And Amortization | us-gaap/2024 | 0 | 0 | monetary | D | D | Cost, Depreciation and Amortization | Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service. |
| Deferred Income Tax Liabilities Net | us-gaap/2024 | 0 | 0 | monetary | I | C | Deferred Income Tax Liabilities, Net | Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Financing Activities | Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. |
| Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Preferred Stock, Par or Stated Value Per Share | Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. | |
| Other Nonoperating Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Nonoperating Income (Expense) | Amount of income (expense) related to nonoperating activities, classified as other. |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | 0 | 0 | monetary | D | C | APIC, Share-Based Payment Arrangement, Increase for Cost Recognition | Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. |
| Deferred Income Taxes And Tax Credits | us-gaap/2024 | 0 | 0 | monetary | D | D | Deferred Income Taxes and Tax Credits | Amount of deferred income tax expense (benefit) and income tax credits. |
| Earnings Per Share Basic | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Increase Decrease In Accounts Payable And Accrued Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable and Accrued Liabilities | The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. |
| Net Cash Provided By Used In Investing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Investing Activities | Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. |
| Payment For Contingent Consideration Liability Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | C | Payment for Contingent Consideration Liability, Financing Activities | Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date. |
| Preferred Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Authorized | The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. | |
| Proceeds From Issuance Of Common Stock | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Issuance of Common Stock | The cash inflow from the additional capital contribution to the entity. |
| Comprehensive Income Loss Attributable To Noncontrolling Interest Continuing Operations | 0001628280-25-022401 | 1 | 0 | monetary | D | C | Comprehensive Income (Loss) Attributable To Noncontrolling Interest - Continuing Operations | Comprehensive Income (Loss) Attributable To Noncontrolling Interest - Continuing Operations |
| Stock Issued During Period Value New Issues | us-gaap/2024 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, New Issues | Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. |
| Long Term Debt Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Long-Term Debt, Current Maturities | Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. |
| Long Term Debt Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Long-Term Debt, Excluding Current Maturities | Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. |
| Minority Interest | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Attributable to Noncontrolling Interest | Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity. |
| Provision For Doubtful Accounts | us-gaap/2024 | 0 | 0 | monetary | D | D | Accounts Receivable, Credit Loss Expense (Reversal) | Amount of expense (reversal of expense) for expected credit loss on accounts receivable. |
| Repayments Of Long Term Lines Of Credit | us-gaap/2024 | 0 | 0 | monetary | D | C | Repayments of Long-Term Lines of Credit | The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer. |
| Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Basic | Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0001628280-25-022401 | 2 | 1 | IS | 0 | H | Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | Net sales | 0 |
| 0001628280-25-022401 | 2 | 2 | IS | 0 | H | Cost Of Goods And Services Sold | us-gaap/2024 | Cost of sales (including depreciation and amortization of $10,265 and $10,025, respectively) | 0 |
| 0001628280-25-022401 | 2 | 3 | IS | 0 | H | Gross Profit | us-gaap/2024 | Gross profit | 0 |
| 0001628280-25-022401 | 2 | 4 | IS | 0 | H | Selling General And Administrative Expense | us-gaap/2024 | Selling, general and administrative expense | 0 |
| 0001628280-25-022401 | 2 | 5 | IS | 0 | H | Research And Development Expense | us-gaap/2024 | Research and development expense | 0 |
| 0001628280-25-022401 | 2 | 6 | IS | 0 | H | Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | us-gaap/2024 | Change in fair value of contingent consideration | 0 |
| 0001628280-25-022401 | 2 | 7 | IS | 0 | H | Depreciation And Amortization | us-gaap/2024 | Depreciation and amortization | 0 |
| 0001628280-25-022401 | 2 | 8 | IS | 0 | H | Gain Loss On Sale Of Business | us-gaap/2024 | Loss on disposals | 1 |
| 0001628280-25-022401 | 2 | 9 | IS | 0 | H | Operating Income Loss | us-gaap/2024 | Operating income | 0 |
| 0001628280-25-022401 | 2 | 10 | IS | 0 | H | Interest Income Expense Nonoperating Net | us-gaap/2024 | Interest expense, net | 1 |
| 0001628280-25-022401 | 2 | 11 | IS | 0 | H | Other Nonoperating Income Expense | us-gaap/2024 | Other expense, net | 1 |
| 0001628280-25-022401 | 2 | 12 | IS | 0 | H | Nonoperating Income Expense | us-gaap/2024 | Other expense | 1 |
| 0001628280-25-022401 | 2 | 13 | IS | 0 | H | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2024 | Loss before income taxes | 0 |
| 0001628280-25-022401 | 2 | 14 | IS | 0 | H | Income Tax Expense Benefit | us-gaap/2024 | Income tax (benefit) expense, net | 0 |
| 0001628280-25-022401 | 2 | 15 | IS | 0 | H | Profit Loss | us-gaap/2024 | Net loss | 0 |
| 0001628280-25-022401 | 2 | 16 | IS | 0 | H | Net Income Loss Attributable To Noncontrolling Interest | us-gaap/2024 | Loss attributable to noncontrolling interest | 1 |
| 0001628280-25-022401 | 2 | 17 | IS | 0 | H | Net Income Loss | us-gaap/2024 | Net loss attributable to Bioventus Inc. | 0 |
| 0001628280-25-022401 | 2 | 18 | IS | 0 | H | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | us-gaap/2024 | Change in foreign currency translation adjustments | 0 |
| 0001628280-25-022401 | 2 | 19 | IS | 0 | H | Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | Comprehensive loss | 0 |
| 0001628280-25-022401 | 2 | 20 | IS | 0 | H | Comprehensive Income Loss Attributable To Noncontrolling Interest Continuing Operations | 0001628280-25-022401 | Comprehensive loss attributable to noncontrolling interest | 0 |
| 0001628280-25-022401 | 2 | 21 | IS | 0 | H | Comprehensive Income Net Of Tax | us-gaap/2024 | Comprehensive loss attributable to Bioventus Inc. | 0 |
| 0001628280-25-022401 | 2 | 23 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2024 | Loss per share of class A common stock, basic (in dollars per share) | 0 |
| 0001628280-25-022401 | 2 | 24 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2024 | Loss per share of class A common stock, diluted (in dollars per share) | 0 |
| 0001628280-25-022401 | 2 | 26 | IS | 0 | H | Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | Basic (in shares) | 0 |
| 0001628280-25-022401 | 2 | 27 | IS | 0 | H | Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | Diluted (in shares) | 0 |
| 0001628280-25-022401 | 3 | 1 | IS | 1 | H | Cost Of Goods And Services Sold Depreciation And Amortization | us-gaap/2024 | Depreciation and amortization | 0 |
| 0001628280-25-022401 | 4 | 9 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0001628280-25-022401 | 4 | 10 | BS | 0 | H | Accounts Receivable Net Current | us-gaap/2024 | Accounts receivable, net | 0 |
| 0001628280-25-022401 | 4 | 11 | BS | 0 | H | Inventory Net | us-gaap/2024 | Inventory | 0 |
| 0001628280-25-022401 | 4 | 12 | BS | 0 | H | Prepaid Expense And Other Assets Current | us-gaap/2024 | Prepaid and other current assets | 0 |
| 0001628280-25-022401 | 4 | 13 | BS | 0 | H | Assets Current | us-gaap/2024 | Total current assets | 0 |
| 0001628280-25-022401 | 4 | 14 | BS | 0 | H | Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | us-gaap/2024 | Property and equipment, net | 0 |
| 0001628280-25-022401 | 4 | 15 | BS | 0 | H | Goodwill | us-gaap/2024 | Goodwill | 0 |
| 0001628280-25-022401 | 4 | 16 | BS | 0 | H | Intangible Assets Net Excluding Goodwill | us-gaap/2024 | Intangible assets, net | 0 |
| 0001628280-25-022401 | 4 | 17 | BS | 0 | H | Operating Lease Right Of Use Asset | us-gaap/2024 | Operating lease assets | 0 |
| 0001628280-25-022401 | 4 | 18 | BS | 0 | H | Deferred Income Tax Assets Net | us-gaap/2024 | Deferred tax assets | 0 |
| 0001628280-25-022401 | 4 | 19 | BS | 0 | H | Long Term Investments | us-gaap/2024 | Investment and other assets | 0 |
| 0001628280-25-022401 | 4 | 20 | BS | 0 | H | Assets | us-gaap/2024 | Total assets | 0 |
| 0001628280-25-022401 | 4 | 23 | BS | 0 | H | Accounts Payable Current | us-gaap/2024 | Accounts payable | 0 |
| 0001628280-25-022401 | 4 | 24 | BS | 0 | H | Accrued Liabilities Current | us-gaap/2024 | Accrued liabilities | 0 |
| 0001628280-25-022401 | 4 | 25 | BS | 0 | H | Long Term Debt Current | us-gaap/2024 | Current portion of long-term debt | 0 |
| 0001628280-25-022401 | 4 | 26 | BS | 0 | H | Business Combination Contingent Consideration Liability Current | us-gaap/2024 | Current portion of contingent consideration | 0 |
| 0001628280-25-022401 | 4 | 27 | BS | 0 | H | Other Liabilities Current | us-gaap/2024 | Other current liabilities | 0 |
| 0001628280-25-022401 | 4 | 28 | BS | 0 | H | Liabilities Current | us-gaap/2024 | Total current liabilities | 0 |
| 0001628280-25-022401 | 4 | 29 | BS | 0 | H | Long Term Debt Noncurrent | us-gaap/2024 | Long-term debt, less current portion | 0 |
| 0001628280-25-022401 | 4 | 30 | BS | 0 | H | Deferred Income Tax Liabilities Net | us-gaap/2024 | Deferred income tax liabilities | 0 |
| 0001628280-25-022401 | 4 | 31 | BS | 0 | H | Other Liabilities Noncurrent | us-gaap/2024 | Other long-term liabilities | 0 |
| 0001628280-25-022401 | 4 | 32 | BS | 0 | H | Liabilities | us-gaap/2024 | Total liabilities | 0 |
| 0001628280-25-022401 | 4 | 33 | BS | 0 | H | Commitments And Contingencies | us-gaap/2024 | Commitments and contingencies (Note 10) | 0 |
| 0001628280-25-022401 | 4 | 35 | BS | 0 | H | Common Stock Value | us-gaap/2024 | Common stock, value | 0 |
| 0001628280-25-022401 | 4 | 36 | BS | 0 | H | Additional Paid In Capital | us-gaap/2024 | Additional paid-in capital | 0 |
| 0001628280-25-022401 | 4 | 37 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2024 | Accumulated deficit | 0 |
| 0001628280-25-022401 | 4 | 38 | BS | 0 | H | Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | Accumulated other comprehensive loss | 0 |
| 0001628280-25-022401 | 4 | 39 | BS | 0 | H | Stockholders Equity | us-gaap/2024 | Total stockholders equity attributable to Bioventus Inc. | 0 |
| 0001628280-25-022401 | 4 | 40 | BS | 0 | H | Minority Interest | us-gaap/2024 | Noncontrolling interest | 0 |
| 0001628280-25-022401 | 4 | 41 | BS | 0 | H | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | Total stockholders equity | 0 |
| 0001628280-25-022401 | 4 | 42 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2024 | Total liabilities and stockholders equity | 0 |
| 0001628280-25-022401 | 5 | 7 | BS | 1 | H | Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | Preferred stock, par value (in dollars per share) | 0 |
| 0001628280-25-022401 | 5 | 8 | BS | 1 | H | Preferred Stock Shares Authorized | us-gaap/2024 | Preferred stock, shares authorized (in shares) | 0 |
| 0001628280-25-022401 | 5 | 9 | BS | 1 | H | Preferred Stock Shares Issued | us-gaap/2024 | Preferred stock, shares issued (in shares) | 0 |
| 0001628280-25-022401 | 5 | 10 | BS | 1 | H | Common Stock Par Or Stated Value Per Share | us-gaap/2024 | Common stock, par value (in dollars per share) | 0 |
| 0001628280-25-022401 | 5 | 11 | BS | 1 | H | Common Stock Shares Authorized | us-gaap/2024 | Common stock, shares authorized (in shares) | 0 |
| 0001628280-25-022401 | 5 | 12 | BS | 1 | H | Common Stock Shares Outstanding | us-gaap/2024 | Common stock, shares outstanding (in shares) | 0 |
| 0001628280-25-022401 | 5 | 13 | BS | 1 | H | Common Stock Shares Issued | us-gaap/2024 | Common stock, shares issued (in shares) | 0 |
| 0001628280-25-022401 | 6 | 15 | EQ | 0 | H | Common Stock Shares Outstanding | us-gaap/2024 | Beginning balance (in shares) | 0 |
| 0001628280-25-022401 | 6 | 16 | EQ | 0 | H | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | Beginning balance | 0 |
| 0001628280-25-022401 | 6 | 17 | EQ | 0 | H | Stock Issued During Period Shares New Issues | us-gaap/2024 | Issuance of Class A common stock for equity plans (in shares) | 0 |
| 0001628280-25-022401 | 6 | 18 | EQ | 0 | H | Stock Issued During Period Value New Issues | us-gaap/2024 | Issuance of Class A common stock for equity plans | 0 |
| 0001628280-25-022401 | 6 | 19 | EQ | 0 | H | Profit Loss | us-gaap/2024 | Net loss | 0 |
| 0001628280-25-022401 | 6 | 20 | EQ | 0 | H | Noncontrolling Interest Increase Decrease From Business Combination | 0001628280-25-022401 | Change in noncontrolling interest allocation | 0 |
| 0001628280-25-022401 | 6 | 21 | EQ | 0 | H | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | Equity-based compensation | 0 |
| 0001628280-25-022401 | 6 | 22 | EQ | 0 | H | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | us-gaap/2024 | Translation adjustment | 0 |
| 0001628280-25-022401 | 6 | 23 | EQ | 0 | H | Common Stock Shares Outstanding | us-gaap/2024 | Ending balance (in shares) | 0 |
| 0001628280-25-022401 | 6 | 24 | EQ | 0 | H | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | Ending balance | 0 |
| 0001628280-25-022401 | 7 | 2 | CF | 0 | H | Profit Loss | us-gaap/2024 | Net loss | 0 |
| 0001628280-25-022401 | 7 | 4 | CF | 0 | H | Depreciation Depletion And Amortization | us-gaap/2024 | Depreciation and amortization | 0 |
| 0001628280-25-022401 | 7 | 5 | CF | 0 | H | Provision For Doubtful Accounts | us-gaap/2024 | Provision (benefit) for credit losses | 0 |
| 0001628280-25-022401 | 7 | 6 | CF | 0 | H | Share Based Compensation | us-gaap/2024 | Equity-based compensation | 0 |
| 0001628280-25-022401 | 7 | 7 | CF | 0 | H | Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | us-gaap/2024 | Change in fair value of contingent consideration | 0 |
| 0001628280-25-022401 | 7 | 8 | CF | 0 | H | Deferred Income Taxes And Tax Credits | us-gaap/2024 | Deferred income taxes | 0 |
| 0001628280-25-022401 | 7 | 9 | CF | 0 | H | Gain Loss On Sale Of Business | us-gaap/2024 | Loss on disposals | 1 |
| 0001628280-25-022401 | 7 | 10 | CF | 0 | H | Foreign Currency Transaction Gain Loss Unrealized | us-gaap/2024 | Unrealized (gain) loss on foreign currency fluctuations | 1 |
| 0001628280-25-022401 | 7 | 11 | CF | 0 | H | Other Operating Activities Cash Flow Statement | us-gaap/2024 | Other, net | 0 |
| 0001628280-25-022401 | 7 | 13 | CF | 0 | H | Increase Decrease In Accounts Receivable | us-gaap/2024 | Accounts receivable | 1 |
| 0001628280-25-022401 | 7 | 14 | CF | 0 | H | Increase Decrease In Inventories | us-gaap/2024 | Inventories | 1 |
| 0001628280-25-022401 | 7 | 15 | CF | 0 | H | Increase Decrease In Accounts Payable And Accrued Liabilities | us-gaap/2024 | Accounts payable and accrued expenses | 0 |
| 0001628280-25-022401 | 7 | 16 | CF | 0 | H | Increase Decrease In Other Operating Capital Net | us-gaap/2024 | Other current and noncurrent assets and liabilities | 1 |
| 0001628280-25-022401 | 7 | 17 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2024 | Net cash from operating activities | 0 |
| 0001628280-25-022401 | 7 | 19 | CF | 0 | H | Payments To Acquire Property Plant And Equipment | us-gaap/2024 | Purchase of property and equipment | 1 |
| 0001628280-25-022401 | 7 | 20 | CF | 0 | H | Proceeds From Payments For Acquisition Of Intangible Assets And Investments | 0001628280-25-022401 | Investments and acquisition of distribution rights | 0 |
| 0001628280-25-022401 | 7 | 21 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2024 | Net cash from investing activities | 0 |
| 0001628280-25-022401 | 7 | 23 | CF | 0 | H | Proceeds From Issuance Of Common Stock | us-gaap/2024 | Proceeds from issuance of Class A common stock | 0 |
| 0001628280-25-022401 | 7 | 24 | CF | 0 | H | Payment For Contingent Consideration Liability Financing Activities | us-gaap/2024 | Payment of contingent consideration | 1 |
| 0001628280-25-022401 | 7 | 25 | CF | 0 | H | Proceeds From Long Term Lines Of Credit | us-gaap/2024 | Borrowing on revolver | 0 |
| 0001628280-25-022401 | 7 | 26 | CF | 0 | H | Repayments Of Long Term Lines Of Credit | us-gaap/2024 | Payment on revolver | 1 |
| 0001628280-25-022401 | 7 | 27 | CF | 0 | H | Payment Of Debt Refinancing Costs | 0001628280-25-022401 | Debt refinancing costs | 1 |
| 0001628280-25-022401 | 7 | 28 | CF | 0 | H | Repayments Of Other Long Term Debt | us-gaap/2024 | Payments on long-term debt | 1 |
| 0001628280-25-022401 | 7 | 29 | CF | 0 | H | Proceeds From Payments For Other Financing Activities | us-gaap/2024 | Other, net | 0 |
| 0001628280-25-022401 | 7 | 30 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2024 | Net cash from financing activities | 0 |
| 0001628280-25-022401 | 7 | 31 | CF | 0 | H | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Effect of exchange rate changes on cash | 0 |
| 0001628280-25-022401 | 7 | 32 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | Net change in cash and cash equivalents | 0 |
| 0001628280-25-022401 | 7 | 33 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash and cash equivalents at the beginning of the period | 0 |
| 0001628280-25-022401 | 7 | 34 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash and cash equivalents at the end of the period | 0 |
| 0001628280-25-022401 | 7 | 36 | CF | 0 | H | Capital Expenditures Incurred But Not Yet Paid | us-gaap/2024 | Accounts payable for purchase of property, plant and equipment | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |